Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa, Junctional
Conditions
Brief summary
The purpose of this study is to evaluate the use of Apligraf for the treatment of nonhealing wounds in subjects with dystrophic or junctional epidermolysis bullosa. Apligraf will be evaluated for efficacy and safety compared to a conventional nonadherent dressing. A matched-pair design will be used to evaluate Apligraf treatment versus conventional treatment in 68 study pairs.
Interventions
DEVICEApligraf
Up to 3 applications: Day 0, Month 1, Month 2.
Dressing regimen will be comprised of a primary nonadherent dressing, nonstick gauze and standard dressing retainer
Sponsors
Organogenesis
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
2 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Subject is between 2 and 65 years of age. * Subject with clinical and histological diagnosis of junctional or dystrophic EB with documented electron microscopy or immunofluorescence microscopy. * Subject has at least two non-adjacent EB lesions, at least 4 cm apart. The two selected EB lesions must be relatively matched in terms of diagnosis, location, level of erosion and size. Lesions may be on the same limb. * Subject with dystrophic or junctional EB lesions between 10-44 cm2 present for at least 6 weeks. For the purposes of this study, a lesion is defined as a wound resulting from a post blister erosion. * Subject who is a female of child-bearing potential (females \>10 years of age) must have a documented negative urine or serum pregnancy test. Sexually active females must be practicing a medically proven form of contraception during the course of the study period. * Subject or legal guardian must have read, understood and signed an institutional review board (IRB) approved Informed Consent Form or Assent Form. * Subject and/or legal guardian must be able and willing to follow study procedures and instructions.
Exclusion criteria
* Subject with lesions only on the soles, posterior thigh or gluteus maximus. * Subject whose lesion has healed 20% or greater in area from post debridement (if applicable) Baseline Screen (Visit 1) to post debridement Day 0 (Visit 2) as determined by wound tracings. * Subject with uncontrolled diabetes mellitus (glycosylated HbA1C \> 10%), cancer (biopsy confirmed active malignancy), or positive HIV test. * Subject is a child (\<18 years of age) who is currently receiving or has received oral steroid therapy exceeding a total daily dose of 0.5mg/kg for more than two weeks, radiation or other immuno-suppressive therapy which would interfere with wound healing within the past four weeks. * Subject is an adult (\>18 years of age) who is currently receiving or has received chronic high dose steroid therapy exceeding a total daily dose of 20mg for more than two weeks, radiation or other immuno-suppressive therapy which would interfere with wound healing within the past four weeks. * Subject who is currently on or has received topical steroidal therapy within 30 days before screening. Inhaled steroids are allowed. * Subject with the presence of acute infections in the areas intended for treatment. * Subject with a history of squamous cell carcinoma. * Known hypersensitivity to bovine collagen or to the components of the Apligraf agarose shipping medium. * Subject who is lactating or pregnant (hCG positive as determined by lab testing). * Subject is a child (\<18 years of age) with liver (ALT/SGPT, ALP, AST/SGOT, bilirubin, total protein, LDH) and/or renal function (BUN and creatinine) tests \> 2 x upper limit of normal (ULN). Albumin \< 2.0 mg/dL. * Subject is an adult (\>18 years of age) with liver (ALT/SGPT, ALP, AST/SGOT, bilirubin, total protein, LDH) and/or renal function (BUN and creatinine) tests \> 2 x upper limit of normal (ULN). Albumin \< 2.0 mg/dL. * Subject enrolled in any wound or investigational device study for any disease within the past four weeks. * Subject who has received an investigational drug or biological treatment within three months. * Subject previously treated with Apligraf, Dermagraft or any other cell therapy at the target sites. * Subject with a history of alcohol or substance abuse within the previous year, which could interfere with study compliance such as inability to attend scheduled study visits or compliance with home dressing changes. * Subject who, in the opinion of the investigator, for any reason other than those listed above, will not be able to complete the study per protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of Wounds First Achieving 100% Epithelialization of Tissue With the Absence of Drainage (i.e. Complete Wound Closure) Through Study Week 12 | Through 12 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Time Until Complete Closure | through 12 weeks |
| Rate of Complete Wound Closure Over Time | through 12 weeks |
| Recurrence of Epidermolysis Bullosa (EB) Lesions | through 12 months |
| Reduction of Intensity of Pain | through 12 weeks |
| Proportion of Wounds Experiencing an Adverse Event | through 12 months |
Countries
United States
Participant flow
Recruitment details
Subjects were recruited from US hospital-based clinics. Recruitment was from December 2007 to December 2008.
Pre-assignment details
A screening period of 1 week was utilized in the study design prior to randomization of study lesions to Apligraf or control at Day 0.
Participants by arm
| Arm | Count |
|---|---|
| Apligraf/Control Apligraf (a living bilayered cell therapy product) Control (a primary nonadherent dressing, nonstick gauze, retainer dressing) | 1 |
| Total | 1 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Adverse Event | 1 |
Baseline characteristics
| Characteristic | Apligraf/Control |
|---|---|
| Age, Categorical <=18 years | 1 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 1 Participants |
| Region of Enrollment United States | 1 participants |
| Sex: Female, Male Female | 0 Participants |
| Sex: Female, Male Male | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 1 / 1 |
| serious Total, serious adverse events | 0 / 1 |
Outcome results
Primary
Proportion of Wounds First Achieving 100% Epithelialization of Tissue With the Absence of Drainage (i.e. Complete Wound Closure) Through Study Week 12
Time frame: Through 12 weeks
Population: no analysis performed as only 1 subject enrolled
Secondary
Proportion of Wounds Experiencing an Adverse Event
Time frame: through 12 months
Population: There was only 1 enrolled subject in the study; this endpoint was descriptively reported, no statistical analyses were performed.
Secondary
Rate of Complete Wound Closure Over Time
Time frame: through 12 weeks
Population: no analysis performed as only 1 subject enrolled
Secondary
Recurrence of Epidermolysis Bullosa (EB) Lesions
Time frame: through 12 months
Population: no analysis performed as only 1 subject enrolled
Secondary
Reduction of Intensity of Pain
Time frame: through 12 weeks
Population: no analysis performed as only 1 subject enrolled
Secondary
Time Until Complete Closure
Time frame: through 12 weeks
Population: no analysis performed as only 1 subject enrolled